Suchergebnisse - "rucaparib"

PubPharm (404)

51

Attenuation of Tumor Burden in Response to Rucaparib in Lung Adenocarcinoma: The Contribution of Oxidative Stress, Apoptosis, and DNA Damage

in: International Journal of Molecular Sciences | 2023

von Maria Pérez-Peiró | Paula Valentí-Serra | Blanca León-González | +4

52

Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study

in: Cancers | 2023

von Valentina Tuninetti | Eleonora Ghisoni | Sandro Pignata | +22

53

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials

in: Cancers | 2023

von Gartrell C. Bowling | Piragash Swargaloganathan | Carly Heintz | +4

54

LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring

in: Pharmaceutics | 2023

von Giovanni Canil | Marco Orleni | Bianca Posocco | +7

55

Liposome Formulations for the Strategic Delivery of PARP1 Inhibitors: Development and Optimization

in: Nanomaterials | 2023

von Carlota J. F. Conceição | Elin Moe | Paulo A. Ribeiro | +1

56

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data

in: BMC Cancer | 2023

von Qilin Zhang | Yiling Ding | Yamin Shu | +1

57

A Randomized, Double-Blind, Biomarker-Selected, Phase II Clinical Trial of Maintenance Poly ADP-Ribose Polymerase Inhibition With Rucaparib Following Chemotherapy for Metastatic Urothelial Carcinoma

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Crabb, S. | Hussain, S. | Soulis, E. | +18

58

Design and synthesis of benzodiazepines as brain penetrating PARP-1 inhibitors

enthalten in: Journal of enzyme inhibition and medicinal chemistry | 2022

von Yu, J. | Gou, W. | Shang, H. | +6

59

Resistance to Poly (ADP-Ribose) Polymerase Inhibitors (PARPi) : Mechanisms and Potential to Reverse

enthalten in: Current oncology reports | 2022

von Washington, C. | Moore, K.

60

First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer

enthalten in: Cureus | 2022

von Roy, S. | Ghosh, J. | Ganguly, S. | +2